Published in Carcinogenesis on March 06, 2007
Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res (2011) 3.18
The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest (2010) 1.50
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer (2011) 1.26
Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer (2010) 1.17
Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opin Ther Targets (2011) 1.16
Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia (2011) 1.06
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer (2009) 1.01
p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expression. Cancer Prev Res (Phila) (2010) 0.97
Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res Treat (2008) 0.96
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer (2016) 0.93
Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant. J Exp Clin Cancer Res (2008) 0.92
Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. Biomaterials (2014) 0.92
Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res (2012) 0.92
Biological approaches to therapy of pancreatic cancer. Pancreatology (2008) 0.91
Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Ther (2010) 0.90
Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J Haematol (2014) 0.90
Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol Pharm (2011) 0.88
Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. Cancer Lett (2012) 0.88
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res (2011) 0.88
The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis (2010) 0.86
Crude alkaloid extract of Rhazya stricta inhibits cell growth and sensitizes human lung cancer cells to cisplatin through induction of apoptosis. Genet Mol Biol (2013) 0.86
Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro Oncol (2010) 0.86
Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma. Int J Cancer (2013) 0.85
The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. J Pediatr Hematol Oncol (2014) 0.85
Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer (2013) 0.84
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells. J Cancer Res Clin Oncol (2009) 0.84
Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy. J Carcinog Mutagen (2013) 0.83
Garlic constituent diallyl trisulfide suppresses x-linked inhibitor of apoptosis protein in prostate cancer cells in culture and in vivo. Cancer Prev Res (Phila) (2011) 0.83
Inhibition of Sp1 functions by its sequestration into PML nuclear bodies. PLoS One (2014) 0.82
Phenethyl isothiocyanate suppresses inhibitor of apoptosis family protein expression in prostate cancer cells in culture and in vivo. Prostate (2011) 0.81
Enhancement of cellular radiation sensitivity through degradation of Chk1 by the XIAP-XAF1 complex. Cancer Biol Ther (2014) 0.80
Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol (2010) 0.80
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res (2015) 0.79
Significance and relationship between DJ-1 gene and surviving gene expression in laryngeal carcinoma. Eur J Histochem (2011) 0.79
The emerging role of exosomes in survivin secretion. Histol Histopathol (2014) 0.79
Mechanisms and therapeutic implications of cell death induction by indole compounds. Cancers (Basel) (2011) 0.79
Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. PLoS One (2014) 0.79
Combination of four gene markers to detect circulating tumor cells in the peripheral blood of patients with advanced lung adenocarcinoma using real-time PCR. Oncol Lett (2013) 0.79
Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress. J Biol Chem (2013) 0.78
Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties. PLoS One (2015) 0.78
A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells. Cell Death Dis (2014) 0.78
Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model. Photochem Photobiol (2016) 0.78
Induction of tumor cell death through targeting tubulin and evoking dysregulation of cell cycle regulatory proteins by multifunctional cinnamaldehydes. PLoS One (2012) 0.77
Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. J Nutr Biochem (2016) 0.77
1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int J Oncol (2009) 0.77
Assessment of mRNA splice variants by qRT-PCR. Methods Mol Biol (2013) 0.76
The Modulation of Apoptotic Pathways by Gammaherpesviruses. Front Microbiol (2016) 0.76
Recent Advances on Small-Molecule Survivin Inhibitors. Curr Med Chem (2015) 0.76
Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. Clin Transl Med (2017) 0.75
Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS. Int J Oncol (2015) 0.75
Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Lab Invest (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Breast cancer stem cells: an overview. Eur J Cancer (2006) 1.61
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54
Targeting survivin in cancer therapy. Expert Opin Ther Targets (2008) 1.47
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med (2009) 1.24
Dimerizable redox-sensitive triazine-based cationic lipids for in vitro gene delivery. ChemMedChem (2007) 1.12
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest (2002) 1.12
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11
Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica (2009) 1.10
p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res (2002) 1.07
MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets (2011) 1.07
Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol (2010) 1.07
Characterization of novel antisense HIF-1α transcripts in human cancers. Cell Cycle (2011) 1.06
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2008) 1.02
G-quadruplex structures in the human genome as novel therapeutic targets. Molecules (2013) 1.02
TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res (2011) 1.00
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol (2003) 1.00
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 0.99
XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol (2014) 0.99
Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer (2005) 0.98
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther (2005) 0.97
Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer (2010) 0.96
Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies. Int J Cancer (2008) 0.96
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther (2006) 0.96
Synthesis and antitumor activity of 3-(2-phenyl-1,3-thiazol-4-yl)-1H-indoles and 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles. ChemMedChem (2011) 0.93
miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal (2013) 0.92
Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures. Org Biomol Chem (2012) 0.92
Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano (2011) 0.92
Photochemical internalization: a new tool for drug delivery. Curr Pharm Biotechnol (2007) 0.91
Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discov Med (2010) 0.91
A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res (2003) 0.91
TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia (2010) 0.90
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol (2012) 0.90
Telomeres as targets for anticancer therapies. Expert Opin Ther Targets (2011) 0.89
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem Pharmacol (2011) 0.89
Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models. J Med Chem (2013) 0.89
Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer (2003) 0.89
Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem (2013) 0.88
Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des (2013) 0.88
Induction of endoplasmic reticulum stress response by the indole-3-carbinol cyclic tetrameric derivative CTet in human breast cancer cell lines. PLoS One (2012) 0.87
Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol (2007) 0.87
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer (2010) 0.86
Targeting the telosome: therapeutic implications. Biochim Biophys Acta (2009) 0.86
Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. Autophagy (2012) 0.86
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. Int J Oncol (2007) 0.85
Tethering functional ligands onto shell of ultrasound active polymeric microbubbles. Biomacromolecules (2006) 0.85
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. J Med Chem (2012) 0.85
High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. J Transl Med (2013) 0.85
Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis (2004) 0.84
Characterization of stress response in human retinal epithelial cells. J Cell Mol Med (2012) 0.84
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One (2011) 0.83
Novel PVA-based hydrogel microparticles for doxorubicin delivery. Biomacromolecules (2008) 0.83
Mechanisms of action and antiproliferative properties of Brassica oleracea juice in human breast cancer cell lines. J Nutr (2005) 0.82
Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids Surf B Biointerfaces (2013) 0.82
Biomolecular markers of outcome prediction in prostate cancer. Cancer (2009) 0.82
Nestling telomere length does not predict longevity, but covaries with adult body size in wild barn swallows. Biol Lett (2013) 0.82
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis (2003) 0.82
Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate (2003) 0.81
To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2009) 0.81
Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Res (2003) 0.81
The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. Breast Cancer Res (2011) 0.81
Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol Biol (2007) 0.81
Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol (2010) 0.81
Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines. Biochem Pharmacol (2006) 0.81
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. Int J Cancer (2014) 0.80
Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer (2013) 0.80
Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. Int J Oncol (2010) 0.80
A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides. J Med Chem (2014) 0.80
Breast cancer-initiating cells: insights into novel treatment strategies. Cancers (Basel) (2011) 0.79
RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets. Methods Mol Biol (2009) 0.79
Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number. Clin Cancer Res (2013) 0.79